| Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 18.35M | $ 18.95M | $ 21.27M | $ 28.72M | $ 21.60M |
| Gross Profit | $ 5.43M | $ 5.62M | $ 6.71M | $ 11.06M | $ 6.96M |
| Operating Income | $ -477.42K | $ -952.02K | $ -190.48K | $ 4.00M | $ 876.47K |
| EBITDA | $ -327.97K | $ -560.02K | $ 12.28K | $ 4.13M | $ 1.95M |
| Net Income | $ -257.52K | $ -753.50K | $ -98.06K | $ 3.03M | $ 1.86M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.17M | $ 5.40M | $ 6.83M | $ 5.47M | $ 2.90M |
| Total Assets | $ 11.98M | $ 12.87M | $ 12.95M | $ 13.22M | $ 10.91M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -6.17M | $ -5.40M | $ -6.83M | $ -5.47M | $ -2.90M |
| Total Liabilities | $ 1.74M | $ 2.37M | $ 1.70M | $ 1.86M | $ 2.43M |
| Stockholders' Equity | $ 10.24M | $ 10.50M | $ 11.25M | $ 11.35M | $ 8.48M |
| Cash Flow | |||||
| Free Cash Flow | $ 762.59K | $ -1.43M | $ 1.36M | $ 2.69M | $ -573.70K |
| Operating Cash Flow | $ 765.03K | $ -1.35M | $ 1.79M | $ 3.24M | $ -465.77K |
| Investing Cash Flow | $ -2.44K | $ -77.93K | $ -426.84K | $ -502.71K | $ -85.92K |
| Financing Cash Flow | $ 0.00 | $ -1.25K | $ -710.00 | $ -165.20K | $ 0.00 |
PD-RX Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.